- Home
- SLDP vs EPIX Comparison
SLDP vs EPIX Comparison
Compare SLDP & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- EPIX
- Stock Information
- Founded
- SLDP 2011
- EPIX 2009
- Country
- SLDP United States
- EPIX Canada
- Employees
- SLDP N/A
- EPIX N/A
- Industry
- SLDP Electrical Products
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- EPIX Health Care
- Exchange
- SLDP Nasdaq
- EPIX Nasdaq
- Market Cap
- SLDP 230.9M
- EPIX 209.4M
- IPO Year
- SLDP N/A
- EPIX N/A
- Fundamental
- Price
- SLDP $1.02
- EPIX $1.72
- Analyst Decision
- SLDP Buy
- EPIX Hold
- Analyst Count
- SLDP 4
- EPIX 4
- Target Price
- SLDP $2.75
- EPIX $9.50
- AVG Volume (30 Days)
- SLDP 1.9M
- EPIX 2.4M
- Earning Date
- SLDP 11-07-2024
- EPIX 12-10-2024
- Dividend Yield
- SLDP N/A
- EPIX N/A
- EPS Growth
- SLDP N/A
- EPIX N/A
- EPS
- SLDP N/A
- EPIX N/A
- Revenue
- SLDP $18,026,000.00
- EPIX N/A
- Revenue This Year
- SLDP $15.90
- EPIX N/A
- Revenue Next Year
- SLDP $117.35
- EPIX N/A
- P/E Ratio
- SLDP N/A
- EPIX N/A
- Revenue Growth
- SLDP N/A
- EPIX N/A
- 52 Week Low
- SLDP $1.02
- EPIX $1.40
- 52 Week High
- SLDP $2.35
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- SLDP 31.33
- EPIX 23.15
- Support Level
- SLDP $1.06
- EPIX $1.75
- Resistance Level
- SLDP $1.19
- EPIX $1.89
- Average True Range (ATR)
- SLDP 0.07
- EPIX 0.19
- MACD
- SLDP -0.01
- EPIX -0.10
- Stochastic Oscillator
- SLDP 0.00
- EPIX 7.36
About SLDP Solid Power Inc.
Solid Power Inc is engaged in developing all-solid-state battery cell technology to enable the next generation of batteries for the EV and other markets. The company's planned business model is to license its all-solid-state battery cell designs and manufacturing know-how to top tier battery manufacturers or automotive original equipment manufacturers and to sell its sulfide-based solid electrolyte for incorporation into all-solid-state battery cells.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.